Trials / Active Not Recruiting
Active Not RecruitingNCT06873516
Phase 2b Study of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria (CSU)
A Randomized, Double-Blind, Placebo Controlled, Dose-Ranging Study Evaluating the Efficacy and Safety of EVO756 in Adults With Moderate to Severe Chronic Spontaneous Urticaria
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 160 (estimated)
- Sponsor
- Evommune, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe chronic spontaneous urticaria (CSU).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EVO756 | Dose 1 |
| DRUG | EVO756 | Dose 2 |
| DRUG | EVO756 | Dose 3 |
| DRUG | Placebo control | Placebo control |
Timeline
- Start date
- 2025-03-20
- Primary completion
- 2026-05-01
- Completion
- 2026-05-01
- First posted
- 2025-03-12
- Last updated
- 2026-04-09
Locations
53 sites across 3 countries: United States, Canada, Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06873516. Inclusion in this directory is not an endorsement.